EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Baseline Fusobacterium Abundance Predicts Ustekinumab Response in Crohn's Disease: A Prospective Microbiome Cohort Study

Chengran Wang iD, Yanping Hao, Yunyun Liu, Le He, Su Xu, Minna Zhang iD, Xin Wang, Honggang Wang

Microbial Biotechnology · 2025

DOI: 10.1111/1751-7915.70250 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Microbial Biotechnology, 2025. Verfasst von Chengran Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, China. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease, Gastrointestinal Microbiome, Fusobacterium. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Provincial Medical Key Discipline Cultivation Unit, The Affiliated Huai'an First People's Hospital of Nanjing Medical University Research and Innovation Team Project, Jiangsu Provincial Geriatric Health Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut microbiota composition in Crohn's disease (CD) patients may influence their response to ustekinumab (UST) therapy. A total of 51 patients with active CD undergoing UST therapy were prospectively enrolled. Clinical activity was evaluated using the Crohn's Disease Activity Index (CDAI), and faecal microbiota were characterised by 16S rRNA sequencing at baseline and week 24. Microbial compositional and functional alterations were assessed, and their correlations with clinical outcomes were examined. At week 24, 46.7% of patients achieved clinical remission and 82.2% achieved clinical response. At baseline, Megamonas ( p = 0.009) and Erysipelatoclostridium ( p = 0.030) were enriched in the remission group, whereas Fusobacterium ( p = 0.016) was more abundant in the non‐remission group and correlated positively with C‐reactive protein (CRP) but negatively with body mass index (BMI) and serum albumin (ALB). Longitudinal analysis showed that CR patients exhibited increased Clostridium sensu stricto 1 ( p = 0.028) and decreased Granulicatella ( p = 0.043) after 24 weeks. This study provides real‐world evidence supporting the clinical efficacy of UST in Asian patients with active CD. The observed association between elevated baseline Fusobacterium abundance and poorer treatment response suggests a potential microbial influence on therapeutic outcomes. These findings highlight the potential of Fusobacterium as a predictive biomarker for UST response and could provide a rationale for integrating microbiota‐modulating strategies to enhance the efficacy of biologics in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabCrohn DiseaseGastrointestinal MicrobiomeFusobacteriumHumansProspective StudiesMaleFemaleAdultFecesTreatment OutcomeRNA, Ribosomal, 16SMiddle AgedYoung AdultDNA, RibosomalDNA, BacterialSequence Analysis, DNA

Stichwörter der Autor:innen

16s rRNACrohn's diseasefusobacteriumustekinumab

Substanzen

UstekinumabRNA, Ribosomal, 16SDNA, RibosomalDNA, Bacterial

Autor:innen und Institutionen

  • Department of Gastroenterology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, China.
  • Department of Gastroenterology, The Affiliated Yancheng First Hospital of Nanjing University Medical School, Yancheng, China.
  • Department of Gastroenterology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, China.
  • Department of Gastroenterology, PhD, The Affiliated Yancheng Chinese Medicine Hospital of Nanjing University of Chinese Medicine, Yancheng, China.
  • Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

ORCID-Profile: Chengran Wang, Minna Zhang

Förderung

  • Jiangsu Provincial Medical Key Discipline Cultivation Unit
  • The Affiliated Huai'an First People's Hospital of Nanjing Medical University Research and Innovation Team Project
  • Jiangsu Provincial Geriatric Health Research Project

Zitieren

APA

Wang, C., Hao, Y., Liu, Y., He, L., Xu, S., Zhang, M., Wang, X., & Wang, H. (2025). Baseline Fusobacterium Abundance Predicts Ustekinumab Response in Crohn's Disease: A Prospective Microbiome Cohort Study. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.70250

Vancouver

Wang C, Hao Y, Liu Y, He L, Xu S, Zhang M, et al. Baseline Fusobacterium Abundance Predicts Ustekinumab Response in Crohn's Disease: A Prospective Microbiome Cohort Study. Microbial Biotechnology. 2025. doi:10.1111/1751-7915.70250

BibTeX
@article{Wang2025,
  author = {Wang, Chengran and Hao, Yanping and Liu, Yunyun and He, Le and Xu, Su and Zhang, Minna and Wang, Xin and Wang, Honggang},
  title = {Baseline Fusobacterium Abundance Predicts Ustekinumab Response in Crohn's Disease: A Prospective Microbiome Cohort Study},
  journal = {Microbial Biotechnology},
  year = {2025},
  doi = {10.1111/1751-7915.70250}
}
Kostenlos starten →